Ocular Therapeutix (OCUL)
Ocular Therapeutix on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
28.8M
Short interest
settlement 2026-10-15
8.1
Days to cover
+0.8 days vs prior
45.7%
Short share of volume
2026-11-03
4,030
Fails to deliver
settlement 2026-10-13
Thu 4 Feb
Next earnings
estimated date
-$568K
Insider flow, 90 days
0 buys, 8 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in OCUL is 28,760,351 shares, down 1,172,789 shares over the last month. Over the last 48 readings it ranged from 10,467,463 shares (13 December 2024) to 29,933,140 shares (15 September 2026). The latest reading sits at the top of that range. At the reported average volume of 3.6M shares a day that is 8.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ocul" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 28,760,351 | -2.2% | 3,551,362 | 8.10 |
| 2026-09-30 | 29,412,673 | -1.7% | 4,057,160 | 7.25 |
| 2026-09-15 | 29,933,140 | +6.7% | 2,109,453 | 14.19 |
| 2026-08-31 | 28,055,522 | -1.6% | 3,130,920 | 8.96 |
| 2026-08-14 | 28,515,335 | +6.7% | 2,248,116 | 12.68 |
| 2026-07-31 | 26,735,397 | -1.1% | 1,981,296 | 13.49 |
| 2026-07-15 | 27,027,521 | +1.3% | 2,067,987 | 13.07 |
| 2026-06-30 | 26,695,136 | +0.9% | 4,070,456 | 6.56 |
| 2026-06-15 | 26,456,015 | +5.5% | 2,233,292 | 11.85 |
| 2026-05-29 | 25,086,045 | +1.2% | 2,774,994 | 9.04 |
| 2026-05-15 | 24,777,685 | -0.1% | 2,917,209 | 8.49 |
| 2026-04-30 | 24,793,045 | +1.1% | 2,894,022 | 8.57 |
| 2026-04-15 | 24,526,963 | -2.6% | 3,509,392 | 6.99 |
| 2026-03-31 | 25,192,853 | +6.4% | 3,496,818 | 7.20 |
| 2026-03-13 | 23,683,101 | +34.2% | 6,660,775 | 3.56 |
| 2026-02-27 | 17,648,381 | +20.0% | 12,294,841 | 1.44 |
| 2026-02-13 | 14,706,215 | +27.8% | 4,940,376 | 2.98 |
| 2026-01-30 | 11,506,830 | -10.0% | 4,255,250 | 2.70 |
| 2026-01-15 | 12,790,655 | +3.6% | 5,782,461 | 2.21 |
| 2025-12-31 | 12,345,939 | +16.5% | 2,859,553 | 4.32 |
| 2025-12-15 | 10,593,646 | -8.9% | 4,537,813 | 2.33 |
| 2025-11-28 | 11,633,800 | -11.7% | 3,059,476 | 3.80 |
| 2025-11-14 | 13,173,573 | -4.4% | 1,912,802 | 6.89 |
| 2025-10-31 | 13,773,939 | +1.4% | 2,132,143 | 6.46 |
| 2025-10-15 | 13,585,178 | +0.2% | 4,460,874 | 3.05 |
| 2025-09-30 | 13,557,599 | -11.3% | 2,712,846 | 5.00 |
| 2025-09-15 | 15,279,147 | +10.4% | 2,739,608 | 5.58 |
| 2025-08-29 | 13,835,161 | +5.8% | 1,702,499 | 8.13 |
| 2025-08-15 | 13,079,993 | +1.9% | 2,325,356 | 5.62 |
| 2025-07-31 | 12,834,007 | -13.3% | 1,805,351 | 7.11 |
| 2025-07-15 | 14,797,351 | +4.4% | 2,381,735 | 6.21 |
| 2025-06-30 | 14,173,873 | -1.7% | 2,540,829 | 5.58 |
| 2025-06-13 | 14,421,637 | +1.1% | 3,263,266 | 4.42 |
| 2025-05-30 | 14,263,742 | +3.2% | 1,737,331 | 8.21 |
| 2025-05-15 | 13,825,192 | +6.5% | 1,801,331 | 7.67 |
| 2025-04-30 | 12,978,704 | -7.9% | 1,316,220 | 9.86 |
| 2025-04-15 | 14,095,236 | +12.0% | 2,005,397 | 7.03 |
| 2025-03-31 | 12,586,674 | -1.9% | 1,631,809 | 7.71 |
| 2025-03-14 | 12,832,340 | +6.5% | 2,073,246 | 6.19 |
| 2025-02-28 | 12,048,382 | +3.9% | 879,443 | 13.70 |
| 2025-02-14 | 11,601,339 | +6.7% | 1,019,189 | 11.38 |
| 2025-01-31 | 10,872,561 | -2.5% | 876,740 | 12.40 |
| 2025-01-15 | 11,157,592 | +3.9% | 903,986 | 12.34 |
| 2024-12-31 | 10,736,923 | +2.6% | 846,278 | 12.69 |
| 2024-12-13 | 10,467,463 | -1.8% | 811,954 | 12.89 |
| 2024-11-29 | 10,661,069 | -1.1% | 1,012,574 | 10.53 |
| 2024-11-15 | 10,775,955 | -15.0% | 947,710 | 11.37 |
| 2024-10-31 | 12,671,361 | -4.5% | 943,376 | 13.43 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of OCUL volume is 45.7%, down 1.8 points over the last five sessions. Over the last 30 readings it ranged from 26.8% (7 October 2026) to 75.4% (16 October 2026). The latest reading is 5.5 points below the 30-session average of 51.2%, on 570K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 261K | 570K | 45.7% | 0 |
| 2026-11-02 | 353K | 776K | 45.5% | 1,030 |
| 2026-10-30 | 419K | 1.4M | 30.9% | 1,500 |
| 2026-10-29 | 492K | 928K | 53.0% | 1,396 |
| 2026-10-28 | 578K | 1.1M | 54.0% | 0 |
| 2026-10-27 | 423K | 890K | 47.5% | 0 |
| 2026-10-26 | 431K | 770K | 56.0% | 1,638 |
| 2026-10-23 | 475K | 782K | 60.7% | 401 |
| 2026-10-22 | 437K | 831K | 52.6% | 1,559 |
| 2026-10-21 | 718K | 1.2M | 62.4% | 946 |
| 2026-10-20 | 430K | 1.0M | 41.3% | 57,743 |
| 2026-10-19 | 2.3M | 3.8M | 59.9% | 131,787 |
| 2026-10-16 | 737K | 978K | 75.4% | 5 |
| 2026-10-15 | 603K | 1.6M | 38.1% | 1,751 |
| 2026-10-14 | 501K | 820K | 61.1% | 3,147 |
| 2026-10-13 | 718K | 1.3M | 57.1% | 130 |
| 2026-10-12 | 876K | 1.5M | 58.3% | 6,711 |
| 2026-10-09 | 624K | 1.2M | 54.2% | 6,359 |
| 2026-10-08 | 483K | 1.3M | 38.0% | 613 |
| 2026-10-07 | 384K | 1.4M | 26.8% | 1,250 |
| 2026-10-06 | 557K | 1.1M | 49.5% | 3,900 |
| 2026-10-05 | 946K | 2.7M | 34.5% | 0 |
| 2026-10-02 | 1.3M | 2.4M | 53.2% | 1,152 |
| 2026-10-01 | 832K | 1.8M | 46.7% | 6,446 |
| 2026-09-30 | 1.2M | 2.3M | 51.3% | 7,833 |
| 2026-09-29 | 1.1M | 2.2M | 50.8% | 109,654 |
| 2026-09-28 | 3.9M | 6.9M | 56.5% | 412,723 |
| 2026-09-25 | 335K | 551K | 60.8% | 1,000 |
| 2026-09-24 | 411K | 755K | 54.5% | 172 |
| 2026-09-23 | 458K | 780K | 58.7% | 187 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in OCUL is 4,030 shares, up 4,004 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (11 August 2026) to 137,797 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 4,030 | $7.56 | $30K |
| 2026-10-02 | 26 | $7.29 | $190 |
| 2026-09-24 | 18,920 | $10.00 | $189K |
| 2026-09-11 | 23,695 | $10.62 | $252K |
| 2026-09-10 | 13,740 | $11.47 | $158K |
| 2026-09-02 | 98,376 | $10.57 | $1.0M |
| 2026-09-01 | 26,960 | $10.49 | $283K |
| 2026-08-31 | 4,494 | $10.36 | $47K |
| 2026-08-25 | 18,020 | $10.78 | $194K |
| 2026-08-24 | 25,800 | $11.08 | $286K |
| 2026-08-21 | 35,941 | $11.09 | $399K |
| 2026-08-12 | 12,457 | $9.76 | $122K |
| 2026-08-11 | 1 | $9.24 | $9 |
| 2026-08-04 | 2,102 | $8.40 | $18K |
| 2026-07-29 | 35 | $8.45 | $296 |
| 2026-07-28 | 13,695 | $8.64 | $118K |
| 2026-07-22 | 9,460 | $8.93 | $84K |
| 2026-07-21 | 53,595 | $8.71 | $467K |
| 2026-07-20 | 1,322 | $8.97 | $12K |
| 2026-07-17 | 3,878 | $9.17 | $36K |
| 2026-07-14 | 10,381 | $9.88 | $103K |
| 2026-07-13 | 1,993 | $10.20 | $20K |
| 2026-07-10 | 294 | $10.54 | $3K |
| 2026-07-09 | 28 | $10.27 | $288 |
| 2026-07-06 | 29,482 | $9.64 | $284K |
| 2026-07-02 | 72 | $9.47 | $682 |
| 2026-07-01 | 284 | $9.82 | $3K |
| 2026-06-30 | 137,797 | $9.90 | $1.4M |
| 2026-06-29 | 33,520 | $9.84 | $330K |
| 2026-06-26 | 4,653 | $9.76 | $45K |
Insider trades
SEC Form 4, newest first. JSONInsiders at OCUL reported 8 open-market sells worth $568K in the last 90 days and no open-market buys. Latest filing: Anderman Todd (Chief Legal Officer) on 2026-10-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | Anderman Todd | Chief Legal Officer | Sell | 12K | $7.29 | $87K | 140K |
| 2026-10-02 | Kaiser Peter | Chief Development Officer | Sell | 10K | $7.05 | $70K | 254K |
| 2026-10-02 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 11K | $7.05 | $77K | 307K |
| 2026-08-31 | Notman Donald | Chief Operating Officer | Sell | 1K | $10.24 | $11K | 367K |
| 2026-08-25 | Dugel Pravin | See Remarks | Gift | 50K | $0.00 | $0 | 745K |
| 2026-08-25 | Dugel Pravin | See Remarks | Gift | 50K | $0.00 | $0 | 0 |
| 2026-08-24 | Nayak Sanjay | Chief Strategy Officer | Sell | 2K | $10.78 | $20K | 327K |
| 2026-08-24 | Kaiser Peter | Chief Development Officer | Sell | 3K | $10.77 | $33K | 264K |
| 2026-08-24 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3K | $10.78 | $36K | 318K |
| 2026-08-24 | Dugel Pravin | See Remarks | Sell | 22K | $10.77 | $233K | 2.5M |
| 2026-06-16 | Dugel Pravin | See Remarks | Gift | 50K | $0.00 | $0 | 2.5M |
| 2026-06-16 | Dugel Pravin | See Remarks | Gift | 50K | $0.00 | $0 | 50K |
| 2026-06-10 | Williams Leslie J. | Director | Grant | 14K | $0.00 | $0 | 65K |
| 2026-06-10 | RAINES MERILEE | Director | Grant | 14K | $0.00 | $0 | 61K |
| 2026-06-10 | LINDSTROM RICHARD L MD | Director | Grant | 14K | $0.00 | $0 | 261K |
| 2026-06-10 | Hong Seung Suh | Director | Grant | 14K | $0.00 | $0 | 61K |
| 2026-06-10 | Robins Jason Shand | Chief Financial Officer | Grant | 15K | $0.00 | $0 | 68K |
| 2026-06-10 | Graves Adrienne L | Director | Grant | 14K | $0.00 | $0 | 64K |
| 2026-06-10 | Warden Charles M | Director | Grant | 14K | $0.00 | $0 | 100K |
| 2026-06-03 | Waheed Nadia | Chief Medical Officer | Sell | 15K | $8.27 | $123K | 300K |
| 2026-05-28 | Dugel Pravin | See Remarks | Gift | 395K | $0.00 | $0 | 695K |
| 2026-05-28 | Dugel Pravin | See Remarks | Gift | 395K | $0.00 | $0 | 0 |
| 2026-05-26 | Nayak Sanjay | Chief Strategy Officer | Sell | 2K | $8.20 | $15K | 329K |
| 2026-05-26 | Kaiser Peter | Chief Development Officer | Sell | 3K | $8.20 | $24K | 266K |
| 2026-05-26 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3K | $8.20 | $25K | 320K |
| 2026-05-26 | Dugel Pravin | See Remarks | Sell | 21K | $8.20 | $173K | 2.6M |
| 2026-04-09 | Dugel Pravin | See Remarks | Gift | 395K | $0.00 | $0 | 395K |
| 2026-04-09 | Dugel Pravin | See Remarks | Gift | 395K | $0.00 | $0 | 2.6M |
| 2026-02-23 | Nayak Sanjay | Chief Strategy Officer | Sell | 2K | $8.28 | $15K | 331K |
| 2026-02-23 | Kaiser Peter | Chief Development Officer | Sell | 3K | $8.28 | $23K | 269K |
| 2026-02-23 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3K | $8.28 | $25K | 323K |
| 2026-02-23 | Dugel Pravin | See Remarks | Sell | 20K | $8.28 | $166K | 3.0M |
| 2026-02-20 | Waheed Nadia | Chief Medical Officer | Sell | 4K | $7.74 | $27K | 315K |
| 2026-02-20 | LINDSTROM RICHARD L MD | Director | Buy | 60K | $7.66 | $461K | 247K |
| 2026-02-12 | Waheed Nadia | Chief Medical Officer | Sell | 8K | $9.04 | $71K | 318K |
| 2026-02-12 | Notman Donald | Chief Operating Officer | Sell | 11K | $9.04 | $103K | 366K |
| 2026-02-12 | Nayak Sanjay | Chief Strategy Officer | Sell | 10K | $9.04 | $94K | 332K |
| 2026-02-12 | Dugel Pravin | See Remarks | Sell | 125K | $9.04 | $1.1M | 3.0M |
| 2026-02-04 | Notman Donald | Chief Operating Officer | Sell | 6K | $8.54 | $52K | 378K |
| 2026-02-02 | Notman Donald | Chief Operating Officer | Sell | 5K | $9.14 | $50K | 384K |
| 2026-01-21 | Robinson David Wayne | Global CCO | Grant | 136K | $0.00 | $0 | 136K |
| 2026-01-02 | Saroj Namrata | Chief Business Officer | Grant | 79K | $0.00 | $0 | 255K |
| 2026-01-02 | Waheed Nadia | Chief Medical Officer | Grant | 79K | $0.00 | $0 | 326K |
| 2026-01-02 | Notman Donald | See Remarks | Grant | 79K | $0.00 | $0 | 389K |
| 2026-01-02 | Nayak Sanjay | Chief Strategy Officer | Grant | 65K | $0.00 | $0 | 343K |
| 2026-01-02 | Meyers Steve Lawrence | Chief Commercial Officer | Grant | 65K | $0.00 | $0 | 218K |
| 2026-01-02 | Kaiser Peter | Chief Development Officer | Grant | 79K | $0.00 | $0 | 272K |
| 2026-01-02 | Heier Jeffrey S. | Chief Scientific Officer | Grant | 79K | $0.00 | $0 | 326K |
| 2026-01-02 | Anderman Todd | Chief Legal Officer | Grant | 65K | $0.00 | $0 | 152K |
| 2025-11-26 | Dugel Pravin | See Remarks | Gift | 50K | $0.00 | $0 | 300K |
| 2025-11-26 | Dugel Pravin | See Remarks | Gift | 50K | $0.00 | $0 | 0 |
| 2025-11-24 | Nayak Sanjay | Chief Strategy Officer | Sell | 2K | $12.04 | $23K | 278K |
| 2025-11-24 | Kaiser Peter | Chief Development Officer | Sell | 3K | $12.02 | $36K | 191K |
| 2025-11-24 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3K | $12.04 | $42K | 246K |
| 2025-11-24 | Dugel Pravin | See Remarks | Sell | 20K | $12.04 | $235K | 3.2M |
| 2025-11-05 | Saroj Namrata | Chief Business Officer | Sell | 26K | $10.74 | $278K | 174K |
| 2025-10-08 | Anderman Todd | Chief Legal Officer | Sell | 11K | $12.34 | $137K | 88K |
| 2025-10-02 | Kaiser Peter | Chief Development Officer | Sell | 10K | $11.03 | $106K | 194K |
| 2025-10-02 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 11K | $11.04 | $116K | 249K |
| 2025-09-09 | Dugel Pravin | See Remarks | Gift | 50K | $0.00 | $0 | 50K |
| 2025-09-09 | Dugel Pravin | See Remarks | Gift | 50K | $0.00 | $0 | 3.2M |
| 2025-09-02 | Notman Donald | See Remarks | Sell | 1K | $12.43 | $13K | 309K |
| 2025-08-25 | Nayak Sanjay | Chief Strategy Officer | Sell | 2K | $12.04 | $23K | 280K |
| 2025-08-25 | Kaiser Peter | Chief Development Officer | Sell | 3K | $12.04 | $36K | 204K |
| 2025-08-25 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3K | $12.04 | $37K | 260K |
| 2025-08-25 | Dugel Pravin | See Remarks | Sell | 21K | $12.04 | $259K | 3.2M |
| 2025-08-12 | Waheed Nadia | Chief Medical Officer | Grant | 40K | $0.00 | $0 | 247K |
| 2025-08-11 | Dugel Pravin | See Remarks | Gift | 250K | $0.00 | $0 | 250K |
| 2025-06-12 | Dugel Pravin | See Remarks | Gift | 50K | $0.00 | $0 | 3.2M |
| 2025-06-11 | RAINES MERILEE | Director | Grant | 14K | $0.00 | $0 | 47K |
| 2025-06-11 | Williams Leslie J. | Director | Grant | 14K | $0.00 | $0 | 51K |
| 2025-06-11 | Warden Charles M | Director | Grant | 14K | $0.00 | $0 | 86K |
| 2025-06-11 | LINDSTROM RICHARD L MD | Director | Grant | 14K | $0.00 | $0 | 143K |
| 2025-06-11 | Hong Seung Suh | Director | Grant | 14K | $0.00 | $0 | 47K |
| 2025-06-11 | Graves Adrienne L | Director | Grant | 14K | $0.00 | $0 | 50K |
| 2025-06-02 | Waheed Nadia | Chief Medical Officer | Sell | 14K | $8.05 | $112K | 207K |
| 2025-05-23 | Dugel Pravin | See Remarks | Sell | 21K | $7.18 | $152K | 3.5M |
| 2025-05-23 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3K | $7.18 | $22K | 263K |
| 2025-05-23 | Kaiser Peter | Chief Development Officer | Sell | 3K | $7.17 | $21K | 207K |
| 2025-05-23 | Nayak Sanjay | Chief Strategy Officer | Sell | 2K | $7.17 | $13K | 282K |
| 2025-05-08 | LINDSTROM RICHARD L MD | Director | Buy | 10K | $6.96 | $70K | 173K |
| 2025-04-28 | Dugel Pravin | See Remarks | Gift | 200K | $0.00 | $0 | 3.3M |
| 2025-02-24 | Nayak Sanjay | Chief Strategy Officer | Sell | 2K | $6.84 | $13K | 283K |
| 2025-02-24 | Kaiser Peter | Chief Development Officer | Sell | 3K | $6.87 | $21K | 210K |
| 2025-02-24 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3K | $6.87 | $21K | 266K |
| 2025-02-24 | Dugel Pravin | See Remarks | Sell | 21K | $6.87 | $148K | 3.5M |
| 2025-02-11 | Nayak Sanjay | Chief Strategy Officer | Grant | 111K | $0.00 | $0 | 285K |
| 2025-02-11 | Notman Donald | See Remarks | Grant | 115K | $0.00 | $0 | 308K |
| 2025-02-11 | Waheed Nadia | Chief Medical Officer | Grant | 79K | $0.00 | $0 | 221K |
| 2025-02-11 | Dugel Pravin | See Remarks | Grant | 1.3M | $0.00 | $0 | 2.0M |
| 2025-02-11 | Dugel Pravin | See Remarks | Grant | 1.5M | $0.00 | $0 | 3.5M |
| 2025-02-04 | Notman Donald | See Remarks | Sell | 11K | $7.81 | $87K | 193K |
| 2025-01-31 | Notman Donald | See Remarks | Sell | 6K | $7.84 | $49K | 205K |
| 2024-11-25 | Dugel Pravin | See Remarks | Sell | 21K | $9.01 | $186K | 792K |
| 2024-11-25 | Nayak Sanjay | Chief Strategy Officer | Sell | 2K | $9.00 | $16K | 174K |
| 2024-11-25 | Kaiser Peter | Chief Development Officer | Sell | 3K | $9.01 | $26K | 213K |
| 2024-11-25 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3K | $9.01 | $27K | 269K |
| 2024-10-07 | Anderman Todd | Chief Legal Officer | Grant | 99K | $0.00 | $0 | 99K |
| 2024-10-02 | Heier Jeffrey S. | Chief Scientific Officer | Grant | 100K | $0.00 | $0 | 272K |
| 2024-10-02 | Kaiser Peter | Chief Development Officer | Grant | 100K | $0.00 | $0 | 216K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON35 Form 144 notices on file for OCUL worth $3.8M at the prices reported; 8 in the last 90 days worth $568K. Latest: TODD ANDERMAN filed on 2026-10-08 to sell 11,984 shares ($87K) from 2026-10-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-08 | TODD ANDERMANOfficer | 12K | $87K | 0.005% | 2026-10-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-02 | JEFFREY S. HEIEROfficer | 11K | $77K | 0.005% | 2026-10-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-02 | PETER KAZUO KAISEROfficer | 10K | $70K | 0.005% | 2026-10-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-31 | DONALD D NOTMAN JR.Officer | 1K | $11K | 0.001% | 2026-08-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-24 | SANJAY NAYAKOfficer | 2K | $20K | 0.001% | 2026-08-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-24 | PETER KAZUO KAISEROfficer | 3K | $33K | 0.001% | 2026-08-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-24 | JEFFREY S. HEIEROfficer | 3K | $36K | 0.002% | 2026-08-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-24 | PRAVIN DUGELOfficer | 22K | $233K | 0.010% | 2026-08-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-03 | NADIA K. WAHEEDOfficer | 15K | $123K | 0.007% | 2026-06-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | SANJAY NAYAKOfficer | 2K | $15K | 0.001% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | PETER KAZUO KAISEROfficer | 3K | $24K | 0.001% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | JEFFREY S. HEIEROfficer | 3K | $25K | 0.001% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-26 | PRAVIN DUGELOfficer | 21K | $174K | 0.010% | 2026-05-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-23 | SANJAY NAYAKOfficer | 2K | $15K | 0.001% | 2026-02-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-23 | PETER KAZUO KAISEROfficer | 3K | $23K | 0.001% | 2026-02-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-23 | JEFFREY S. HEIEROfficer | 3K | $25K | 0.001% | 2026-02-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-23 | PRAVIN DUGELOfficer | 20K | $166K | 0.009% | 2026-02-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-20 | NADIA K. WAHEEDOfficer | 4K | $27K | 0.002% | 2026-02-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-12 | NADIA K. WAHEEDOfficer | 8K | $71K | 0.004% | 2026-02-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-12 | DONALD D NOTMAN JR.Officer | 11K | $103K | 0.005% | 2026-02-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-12 | SANJAY NAYAKOfficer | 10K | $94K | 0.005% | 2026-02-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-12 | STEVE MEYERSOfficer | 7K | $62K | 0.003% | 2026-02-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-12 | PRAVIN DUGELOfficer | 125K | $1.1M | 0.057% | 2026-02-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-04 | DONALD D NOTMAN JR.Officer | 6K | $52K | 0.003% | 2026-02-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-04 | STEVE MEYERSOfficer | 4K | $38K | 0.002% | 2026-02-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | DONALD D NOTMAN JR.Officer | 5K | $50K | 0.003% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | STEVE MEYERSOfficer | 3K | $28K | 0.001% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-24 | SANJAY NAYAKOfficer | 2K | $23K | 0.001% | 2025-11-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-24 | PETER KAZUO KAISEROfficer | 3K | $36K | 0.001% | 2025-11-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-24 | JEFFREY S. HEIEROfficer | 3K | $42K | 0.002% | 2025-11-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-24 | PRAVIN DUGELOfficer | 20K | $235K | 0.009% | 2025-11-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-05 | NAMRATA SAROJOfficer | 26K | $278K | 0.012% | 2025-11-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-08 | TODD ANDERMANOfficer | 11K | $137K | 0.006% | 2025-10-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-02 | PETER KAZUO KAISEROfficer | 10K | $107K | 0.006% | 2025-10-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-02 | JEFFREY S. HEIEROfficer | 11K | $116K | 0.006% | 2025-10-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON7 holders report 5% or more of OCUL in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (31,785,634 shares), filed 2025-11-05 for an event on 2025-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-07-29 | 13G/Ano. 6 | BlackRock, Inc.parent holding company | 15.2M | 7.0% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 20.9M | 9.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | David Kroinparent holding company, individual | 20.9M | 9.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 20.9M | 9.5% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 3 | Nimish Shahindividual | 6.9M | 3.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 3 | Bong Y. Kohindividual | 6.9M | 3.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 3 | Venrock Healthcare Capital Partners EG, L.P.partnership | 6.9M | 3.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 3 | Venrock Healthcare Capital Partners III, L.P.partnership | 6.9M | 3.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 3 | VHCP Co-Investment Holdings III, LLCother entity | 6.9M | 3.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 3 | VHCP Management III, LLCother entity | 6.9M | 3.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 3 | VHCP Management EG, LLCother entity | 6.9M | 3.2% | 2025-12-31 |
| 2025-12-08 | 13G | SUMMER ROAD LLCother entity | 12.1M | 5.7% | 2025-12-04 |
| 2025-11-05 | 13G/Ano. 1 | FMR LLCparent holding company | 31.8M | 15.0% | 2025-09-30 |
| 2025-11-05 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 31.8M | 15.0% | 2025-09-30 |
13F holders
Tracked managers holding OCUL at their latest 13F. JSON6 of the 30 tracked managers held OCUL at their latest 13F, $61.6M in total at quarter-end prices. Point72 Asset Management is the largest at $32.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 3.3M | $32.3M | 0.04% | -2.2M |
| Two Sigma Investments | 2026-06-30 | 1.2M | $12.0M | 0.01% | -612K |
| AQR Capital Management | 2026-06-30 | 950K | $9.3M | 0.00% | +451K |
| Renaissance Technologies | 2026-06-30 | 379K | $3.7M | 0.01% | -769K |
| Citadel Advisors | 2026-06-30 | 310K | $3.0M | 0.00% | -325K |
| D. E. Shaw & Co. | 2026-06-30 | 124K | $1.2M | 0.00% | -94K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Ocular Therapeutix reported revenue of $13.5M, up 0.1% from the same quarter a year earlier, and net loss of $78.8M (-0.35 diluted EPS). In FY 2025 it generated -$204.9M of operating cash flow.
- Cash
- $598.6M
- Equity
- $520.0M
- Total assets
- $671.3M
- Shares outstanding
- 219,615,868
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $13.5M | -$78.8M | -584.5% | -0.35 |
| Q1 FY 2026 | 2026-03-31 | $10.8M | -$88.6M | -821.6% | -0.40 |
| Q4 FY 2025derived | 2025-12-31 | $13.3M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $14.5M | -$69.4M | -477.3% | -0.38 |
| Q2 FY 2025 | 2025-06-30 | $13.5M | -$67.8M | -503.9% | -0.39 |
| Q1 FY 2025 | 2025-03-31 | $10.7M | -$64.1M | -598.7% | -0.38 |
| Q4 FY 2024derived | 2024-12-31 | $17.1M | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $15.4M | -$36.5M | -236.6% | -0.22 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $52.0M | -$265.9M | -$204.9M | $12.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $63.7M | -$193.5M | -$134.7M | $1.3M | n/a | n/a |
| FY 2023 | 2023-12-31 | $58.4M | -$80.7M | -$70.2M | $6.1M | n/a | n/a |
| FY 2022 | 2022-12-31 | $51.5M | -$71.0M | -$59.6M | $3.7M | n/a | n/a |
| FY 2021 | 2021-12-31 | $43.5M | -$6.6M | -$65.5M | $1.2M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Ocular Therapeutix in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Ocular Therapeutix (OCUL), SEC CIK 1393434, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-08.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-03.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1393434Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of OCUL is sold short?
28,760,351 shares were held short at the 2026-10-15 settlement, 8.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is OCUL's daily short volume?
On 2026-11-03, 260,592 of the 570,362 OCUL shares reported to FINRA were sold short, 45.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does OCUL have fails to deliver?
The SEC's latest file shows 4,030 OCUL shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are OCUL insiders buying or selling?
Insiders at OCUL reported 8 open-market sells worth $568K in the last 90 days and no open-market buys. Latest filing: Anderman Todd (Chief Legal Officer) on 2026-10-08.
Have OCUL insiders filed to sell?
35 Form 144 notices on file for OCUL worth $3.8M at the prices reported; 8 in the last 90 days worth $568K. Latest: TODD ANDERMAN filed on 2026-10-08 to sell 11,984 shares ($87K) from 2026-10-08.
Who owns 5% or more of OCUL?
7 holders report 5% or more of OCUL in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (31,785,634 shares), filed 2025-11-05 for an event on 2025-09-30.
What did OCUL report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Ocular Therapeutix reported revenue of $13.5M, up 0.1% from the same quarter a year earlier, and net loss of $78.8M (-0.35 diluted EPS). In FY 2025 it generated -$204.9M of operating cash flow.
Which tracked 13F managers own OCUL?
6 of the 30 tracked 13F managers held OCUL shares at their latest filing, $61.6M in all. The largest: Steve Cohen's Point72 Asset Management (3.3M shares, $32.3M), Two Sigma Investments (1.2M shares, $12.0M), Cliff Asness's AQR Capital Management (950K shares, $9.3M), Renaissance Technologies (379K shares, $3.7M), Ken Griffin's Citadel Advisors (310K shares, $3.0M), D. E. Shaw & Co. (124K shares, $1.2M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.